J. Nathaniel Diehl

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Adrienne D. Cox · 9 shared papers, 2019–2026 · strength 1.05
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
2. Channing J. Der · 9 shared papers, 2019–2026 · strength 1.05
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
3. Jennifer E. Klomp · 8 shared papers, 2019–2026 · strength 0.87
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
4. Andrew M. Waters · 7 shared papers, 2019–2026 · strength 0.77
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
5. Priya S. Hibshman · 5 shared papers, 2021–2026 · strength 0.74
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
6. Clint A. Stalnecker · 6 shared papers, 2019–2026 · strength 0.69
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
7. Bjoern Papke · 7 shared papers, 2019–2026 · strength 0.69
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
8. Craig M. Goodwin · 5 shared papers, 2020–2026 · strength 0.62
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. DOI 10.1016/bs.acr.2021.07.008↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
9. Mariaelena Pierobon · 6 shared papers, 2019–2025 · strength 0.60
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
   • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
10. Lee M. Graves · 4 shared papers, 2021–2026 · strength 0.56
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
11. Kirsten L. Bryant · 5 shared papers, 2019–2025 · strength 0.49
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
12. G. Aaron Hobbs · 5 shared papers, 2019–2026 · strength 0.49
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
13. A. Cole Edwards · 3 shared papers, 2021–2026 · strength 0.46
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
14. Emanuel F. Petricoin · 5 shared papers, 2019–2021 · strength 0.41
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
15. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
16. Devon R. Blake · 3 shared papers, 2021–2026 · strength 0.38
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
17. Andrew J. Aguirre · 3 shared papers, 2020–2026 · strength 0.35
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
18. Naim U. Rashid · 2 shared papers, 2021–2025 · strength 0.29
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
19. Kristina Drizyte‐Miller · 2 shared papers, 2021–2025 · strength 0.28
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
20. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
21. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.18
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
22. Jonathan M. DeLiberty · 2 shared papers, 2020–2021 · strength 0.17
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
23. Nina V. Chaika · 2 shared papers, 2019–2020 · strength 0.14
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
    • Paper Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-019-0368-8↗
24. Yan Liang · 2 shared papers, 2019–2020 · strength 0.14
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
    • Paper Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-019-0368-8↗
25. Venugopal Gunda · 2 shared papers, 2019–2020 · strength 0.14
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
    • Paper Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-019-0368-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.